These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37686510)

  • 21. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
    Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
    Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
    World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl-Diethylenetriaminepentaacetic Acid MRI.
    Kunichika H; Minamiguchi K; Tachiiri T; Shimizu K; Taiji R; Yamada A; Nakano R; Irizato M; Yamauchi S; Marugami A; Marugami N; Kishida H; Nakagawa H; Takewa M; Kageyama K; Yamamoto A; Ueshima E; Sofue K; Kita R; Kurakami H; Tanaka T
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging.
    Korkusuz H; Knau LL; Kromen W; Bihrer V; Keese D; Piiper A; Vogl TJ
    J Magn Reson Imaging; 2012 Jun; 35(6):1397-402. PubMed ID: 22267126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma.
    Mukozu T; Nagai H; Nagumo H; Mohri K; Yoshimine N; Kobayashi K; Ogino Y; Matsui T; Daido Y; Wakui N; Momiyama K; Higai K; Matsuda T; Igarashi Y
    Oncology; 2024 Sep; ():1-13. PubMed ID: 39265564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Chiang CL; Chan SK; Lee SF; Choi HC
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of early recurrence of hepatocellular carcinoma after resection based on Gd-EOB-DTPA enhanced magnetic resonance imaging: a preliminary study.
    Zhao QY; Liu SS; Fan MX
    J Gastrointest Oncol; 2022 Apr; 13(2):792-801. PubMed ID: 35557582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.
    Yoo SH; Choi JY; Jang JW; Bae SH; Yoon SK; Kim DG; Yoo YK; Rha SE; Lee YJ; Jung ES
    Ann Surg Oncol; 2013 Sep; 20(9):2893-900. PubMed ID: 23649931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.
    Nosaka T; Murata Y; Akazawa Y; Tanaka T; Takahashi K; Naito T; Matsuda H; Ohtani M; Imamura Y; Nakamoto Y
    Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.
    Liu X; Jiang H; Chen J; Zhou Y; Huang Z; Song B
    Liver Transpl; 2017 Dec; 23(12):1505-1518. PubMed ID: 28886231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
    Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
    Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
    Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
    Abdom Radiol (NY); 2024 Sep; 49(9):3127-3135. PubMed ID: 38678485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters.
    Tang Q; Ma C
    Oncol Lett; 2018 Aug; 16(2):2725-2731. PubMed ID: 30008946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.
    Saito K; Kotake F; Ito N; Ozuki T; Mikami R; Abe K; Shimazaki Y
    Magn Reson Med Sci; 2005; 4(1):1-9. PubMed ID: 16127248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
    Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
    J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.